GXO Logistics, Inc. Q1 FY2025 earnings call

Malcolm Wilson's Remarks

• Delivered strong Q1 results with $3B revenue, 21% YOY growth, and $228M new business wins.
• Highlighted progress in healthcare sector with NHS deal and Siemens Healthineers contract, attributing success to Clipper Logistics acquisition.
• Wincanton integration nearing conclusion, expecting $58M cost synergies.
• Customer satisfaction up nearly 10%, new business with existing customers increased.

Baris Oran's Remarks

• Revenue growth details, organic growth by regions, adjusted EBITDA, and net loss due to one-time charges.
• Operational initiatives for productivity, integration of Wincanton as a catalyst for EBITDA growth, free cash flow, return on invested capital, and share buyback.

Kristine Kubacki's Remarks

• Progress with AI and technology, including AI modules for proactive replenishment, cost savings from AI, and automation in various areas like inbound unloading and inventory cycle counting.

In the first quarter of 2025, GXO generated revenue of $3 billion, which was up 21% year-over-year. Adjusted EBITDA was $163 million. Organic revenue growth was 3%, with all three regions delivering organic growth, led by the Continental European business. The company's M&A strategy is working, as seen in the progress in the healthcare sector, including a landmark $2.5 billion contract with the U.K. National Health Services supply chain. The sales pipeline, excluding Wincanton, grew to a three-year high of $2.5 billion.

Reaffirmed guidance for 2025: organic growth of 3% to 6%, adjusted EBITDA of $840 million to $860 million, adjusted diluted earnings per share of $2.40 to $2.60, and adjusted EBITDA to free cash flow conversion of 25% to 35%. Base case for guidance is flat volumes year-over-year in 2025, and FX is expected to be a tailwind in 2026.

Factors such as fluctuations in foreign exchange rates, changes in global economic conditions, consumer demand, labor market and global supply chain constraints, inflationary pressures. Also, a contingency related to an Italian tax authorities matter with an expected settlement amount of $66 million in 2025.

Q: Talk about the scenario planning behind reaffirming the guidance in the context of uncertain macro and strong 1Q results.

A: Right now, our business is trading well in a dynamic environment, and the base case for our guidance is flat volumes year-over-year in 2025. Should we see a softer environment in the U.S. economy, we estimate that we would still land within our narrow guidance range for 2025.

Q: How should we think about the impact of FX on your results in 2025 and 2026?

A: FX will be a tailwind for us in 2026. Definitely, we will see an improvement if the current rates would stay. But for Q2, we were pretty much fully hedged for Q2 of 2025. For Q3, we are about three quarters hedged. The impact will for '25, Q2 and onwards will be limited and we will see more upside in 2026.

Q: Talk about the NHS deal, including background, opportunities in other healthcare areas, and ramp-up.

A: It's a real landmark deal. We've been working in the healthcare vertical since acquiring Clipper Logistics. It's a huge piece of business with takeover in place of around eight locations, couple of thousand people, several 100 delivery trucks and vans. We're not anticipating significant startup costs. We have a strong pipeline of health-related customers waiting to join us.

Q: Talk about inventory levels, conversations with customers, and bonded warehouses.

A: All three regions have strong performance. Our North American business was strong due to customer mix. We've seen some volume development in first quarter but it's not affecting top line. In terms of bonded warehouses, in North America's consumer vertical, there's been significant increase in requests, but it doesn't have a material impact on financials.

Q: Talk about existing contracts, contract renewals, and potential cliffs.

A: No sign of cliff in contract renewals. Typical contract period is around five years, renewal is a gradual process. We're renewing normal level of contracts every year, with high customer satisfaction.

Q: Talk about cost savings from automation projects, quantification, and ramp.

A: In first quarter, recorded first non-pilot cost savings from proprietary AI implementations. Savings are immaterial for 2025 but will deliver outsized savings in future years. Deploying AI is bespoke to each site but has huge potential.

Q: Talk about pipeline, customer demand, and sales organization redesign.

A: Pipeline is $2.5 billion, up 13% YOY. No material impact from tariffs on sales pipeline. Sales organization redesign in 2024 is paying off, with e-commerce projects reemerging. Geographic exposure and new verticals like healthcare are diversifying the business.

Q: Talk about CMA review process, alternatives, and timeline for integration.

A: Nearing conclusion of CMA process. Preparing for full clearance or disposal of small part of Wincanton business. Timing close to early summer, likely to start integration by quarter two earnings call.

Q: Talk about Italian tax authorities dispute, reserve, and impact on EPS.

A: Contingency amount $66 million, expected to be settled in 2025. Does not impact 2024 or 2025 adjusted EBITDA or adjusted EPS as cash was booked into separate account.

Q: Talk about seasonality of business, EBITDA ramp, and Chinese import product exposure.

A: EBITDA ramp reflects maturing startups and productivities. Customers have diversified supply chain base, only a small quarter of U.S. retail business exposed to China imports, and no major risk to EBITDA guidance.

Q: Talk about share buybacks, run rate, and thinking on share repurchase.

A: Board authorized $500M share buyback. Purchased 2.8 million shares in first quarter. Will provide update at end of Q2 on share repurchase status.